MNTA TEVA – Highly unlikely, IMO, that anything of consequence to investors is happening with the Copaxone patent litigation, which figures to be a drawn-out affair. Moreover, one could plausibly argue that the FDA rather than the patent litigation is the gating factor on generic Copaxone.
On Copaxone, the initial lovenox filers filed something like 6 years ago, I'd bet the fda takes every bit as long or longer with Copaxone. My bet would be a very slim chance the fda approves without clinical trials and or a very lengthy review. But that's jmo.
Market Data 
Markets 
AI
